Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15325139 | 0.85 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11KDM4E | |
| SCHEMBL3687397 | 0.83 | SLC5A2 (0.45) | SLC5A2SLC5A1ADRA2ASLC5A11KDM4E | |
| SCHEMBL3798878 | 0.82 | SMN1; SMN2 (0.40) | SLC5A2SLC5A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL27771495 | 0.82 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11KDM4E | |
| SCHEMBL3678607 | 0.82 | SLC5A2 (0.48) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3802288 | 0.81 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL14795483 | 0.80 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3684973 | 0.79 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14248461 | 0.78 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13074751 | 0.78 | SLC5A2 (0.43) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019679-B1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-7803778-B2 | Glucose transport inhibitors and methods of use | THERACOS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2019679-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | Theracos, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007140191-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.